Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Endoscopy Every 2 Years or Only as Needed in Monitoring Patients With Barrett Esophagus

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2009 by National Cancer Institute (NCI).
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00987857
First received: September 30, 2009
Last updated: August 9, 2013
Last verified: September 2009
  Purpose

RATIONALE: Screening tests may help doctors find cancer cells early and plan better treatment. It is not yet known whether endoscopy every 2 years is more effective than endoscopy only as needed in finding esophageal cancer in patients with Barrett esophagus.

PURPOSE: This randomized phase III trial is studying endoscopy every 2 years to see how well it works compared with endoscopy only as needed in monitoring patients with Barrett esophagus.


Condition Intervention Phase
Esophageal Cancer
Precancerous Condition
Other: questionnaire administration
Procedure: comparison of screening methods
Procedure: diagnostic endoscopic procedure
Procedure: endoscopic biopsy
Procedure: endoscopic procedure
Procedure: quality-of-life assessment
Procedure: screening method
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Open Label
Primary Purpose: Screening
Official Title: Barrett's Oesophagus Two Yearly Surveillance Versus Endoscopy at Need: a Randomised Controlled Trial to Estimate Effectiveness and Cost-effectiveness Study (BOSS)

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Overall survival [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Cost-effectiveness [ Designated as safety issue: No ]
  • Incidence of esophageal cancer, gastric or esophageal cancer, or all cancers [ Designated as safety issue: No ]
  • Time to diagnosis of esophageal adenocarcinoma [ Designated as safety issue: No ]
  • Stage of esophageal adenocarcinoma at diagnosis using TNM staging [ Designated as safety issue: No ]
  • Morbidity and mortality related to endoscopy, esophageal surgery, and other endoscopy-related interventions [ Designated as safety issue: No ]
  • Frequency of endoscopy [ Designated as safety issue: No ]

Estimated Enrollment: 2500
Study Start Date: March 2009
Detailed Description:

OBJECTIVES:

Primary

  • To establish whether endoscopic surveillance every 2 years or endoscopy at need only is superior in terms of overall survival and, if neither is superior, whether endoscopy at need only is non-inferior to surveillance every 2 years in patients with Barrett esophagus.

Secondary

  • To estimate the cost-effectiveness of endoscopic surveillance every 2 years as compared to endoscopy at need only.
  • To establish whether there is a significant difference between endoscopic surveillance every 2 years or endoscopy at need only in terms of the incidence of esophageal cancer, gastric or esophageal cancer, or all cancers.
  • To establish whether there is a significant difference between endoscopic surveillance every 2 years or endoscopy at need only in terms of the time to diagnosis of esophageal adenocarcinoma.
  • To establish whether there is a significant difference between endoscopic surveillance every 2 years or endoscopy at need only in terms of the stage of esophageal adenocarcinoma at diagnosis using TNM staging.
  • To establish whether there is a significant difference between endoscopic surveillance every 2 years or endoscopy at need only in terms of morbidity and mortality related to endoscopy, esophageal surgery, and other endoscopy-related interventions (e.g., ablation).
  • To establish whether there is a significant difference between endoscopic surveillance every 2 years or endoscopy at need only in terms of the frequency of endoscopy.

OUTLINE: This is a multicenter study. Patients are stratified according to age at diagnosis (< 65 years vs ≥ 65 years), length of Barrett metaplasia segment including tongues (< 2 cm vs ≥ 2 cm and ≤ 3 cm vs > 3 cm and ≤ 8 cm vs > 8 cm), and newly diagnosed disease (defined as the date of endoscopy confirming Barrett metaplasia was within the past 4 months) (yes vs no). Patients are randomized to 1 of 2 intervention arms.

  • Arm I: Patients undergo surveillance endoscopy with quadrantic biopsies taken every 2 cm. Patients undergo endoscopy every 2 years for a total of 6 endoscopies over 10 years.
  • Arm II: Patients undergo endoscopy as needed over 10 years. All patients may undergo urgent endoscopy if they develop dysphagia, unexplained weight loss of > 7 lb, iron-deficiency anemia, recurrent vomiting, or worsening upper gastrointestinal symptoms.

All patients complete a questionnaire that includes a quality-of-life measure and questions about medication at baseline, every 2 years, and following key events (e.g., diagnosis of any cancer or high-grade dysplasia).

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically confirmed circumferential Barrett metaplasia meeting 1 of the following criteria:

    • At least 1 cm from the gastro-esophageal junction
    • At least a 2 cm non-circumferential tongue of Barrett metaplasia
  • Undergone endoscopy within the last 2 years to confirm Barrett metaplasia and exclude high-grade dysplasia and carcinoma
  • No known high-grade dysplasia or carcinoma

PATIENT CHARACTERISTICS:

  • Resident of the United Kingdom
  • Informed of the risk of Barrett esophagus developing into esophageal cancer, either at the visit when the invitation letter is issued or on a documented previous occasion
  • Able to undergo endoscopy
  • No medical conditions that would make endoscopy difficult or hazardous

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00987857

Locations
United Kingdom
Gloucestershire Royal Hospital Recruiting
Gloucester, England, United Kingdom, GL1 3NN
Contact: Hugh Barr    44-8454-225-460      
Sponsors and Collaborators
Gloucestershire Royal Hospital
Investigators
Principal Investigator: Hugh Barr Gloucestershire Royal Hospital
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00987857     History of Changes
Other Study ID Numbers: NHS-GRH-HTA-05/12/01, CDR0000649890, ISRCTN54190466
Study First Received: September 30, 2009
Last Updated: August 9, 2013
Health Authority: Unspecified

Keywords provided by National Cancer Institute (NCI):
esophageal cancer
adenocarcinoma of the esophagus
Barrett esophagus

Additional relevant MeSH terms:
Barrett Esophagus
Esophageal Neoplasms
Precancerous Conditions
Digestive System Abnormalities
Digestive System Diseases
Digestive System Neoplasms
Esophageal Diseases
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Head and Neck Neoplasms
Neoplasms
Neoplasms by Site

ClinicalTrials.gov processed this record on November 25, 2014